Last reviewed · How we verify
SY-005
At a glance
| Generic name | SY-005 |
|---|---|
| Sponsor | Suzhou Yabao Pharmaceutical R&D Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Annexin A5 in Patients With Severe COVID-19 Disease (PHASE2)
- SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis (PHASE2)
- Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SY-005 CI brief — competitive landscape report
- SY-005 updates RSS · CI watch RSS
- Suzhou Yabao Pharmaceutical R&D Co., Ltd. portfolio CI